Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
However, the script later moved the day high at 0.8764, up 10.18%. The company’s stock has a 5-day price change of 15.11% and 59.05% over the past three months. ADAP shares are trading 10.32% year to date (YTD), with the 12-month market performance down to -51.40% lower. It has a 12-month low price of $0.42 and touched a high of $1.95 over the same period. ADAP has an average intraday trading volume of 632.82K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.25%, 41.19%, and 3.23% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) shares accounts for 51.77% of the company’s 226.93M shares outstanding.
It has a market capitalization of $198.52M and a beta (3y monthly) value of 2.23. The earnings-per-share (ttm) stands at -$0.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.37% over the week and 11.81% over the month.
Analysts forecast that Adaptimmune Therapeutics Plc ADR (ADAP) will achieve an EPS of -$0.1 for the current quarter, -$0.14 for the next quarter and -$0.49 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.17 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.18 a year ago. Earnings per share for the fiscal year are expected to decrease by -160.69%, and -11.64% over the next financial year. EPS should grow at an annualized rate of 1.00% over the next five years, compared to -5.40% over the past 5-year period.
Looking at the support for the ADAP, a number of firms have released research notes about the stock. Bryan Garnier stated their Buy rating for the stock in a research note on March 24, 2023, with the firm’s price target at $3.60.
